{"id":39647,"date":"2025-08-19T16:58:00","date_gmt":"2025-08-19T08:58:00","guid":{"rendered":"https:\/\/flcube.com\/?p=39647"},"modified":"2025-08-19T16:58:01","modified_gmt":"2025-08-19T08:58:01","slug":"wuxi-xdc-reports-strong-h1-2025-growth-with-62-2-revenue-increase","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39647","title":{"rendered":"WuXi XDC Reports Strong H1 2025 Growth With 62.2% Revenue Increase"},"content":{"rendered":"\n

China-based WuXi XDC Cayman Inc. (HKG: 2268<\/a>), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in the bioconjugate market, announced its interim results for the first half of 2025. The company achieved a 62.2% year-on-year (YoY) revenue increase to RMB 2,701 million. Net profit grew by 52.7% YoY to RMB 746 million, with a margin of 27.6%.<\/p>\n\n\n\n

Growth Drivers<\/strong>
The significant growth was primarily driven by an increase in the number of customers and projects, reflecting the continued expansion of the global ADC and broader bioconjugate market. The total global customer base expanded to 563, with 64 new customers added in the first half of 2025. WuXi XDC’s established position as a leading ADC CRDMO service provider further boosted market share and advanced projects into later stages. The total number of iCMC projects reached 225, including 37 newly signed iCMC projects in the first half of 2025. The total backlog grew to USD 1,329 million, representing a 57.9% YoY increase.<\/p>\n\n\n\n

Capacity Expansion<\/strong>
WuXi XDC continues to expand its production capacity. The DP3 facility at the Wuxi site achieved GMP release, further enhancing the company’s All-in-One manufacturing capability. The Singapore site completed mechanical construction and is on track to achieve GMP release in the first half of 2026.-Fineline Info & Tech<\/a><\/p>\n\n\n\n